Latest news with #BPMC
Yahoo
2 days ago
- Business
- Yahoo
Why Blueprint Medicines Corporation (BPMC) Skyrocketed On Monday
We recently published a list of . In this article, we are going to take a look at where Blueprint Medicines Corporation (NASDAQ:BPMC) stands against other top-performing stocks on Monday. Blueprint Medicines soared by 26.09 percent on Monday to close at $127.79 each following news that it is set to be acquired by French pharmaceutical giant Sanofi for $9.1 billion. Under the agreement, Sanofi will commence a tender offer to acquire shares of Blueprint Medicines Corporation (NASDAQ:BPMC) at a price of $129 apiece for a total equity value of $9.1 billion. A doctor examining a patient's samples in a modern hospital setting. In addition, shareholders will be able to receive one non-tradable contingent value right (CVR), which will entitle them to two potential milestone payments of $2 and $4 per CVR for the achievement, respectively, of future development and regulatory milestones for BLU-808. The upfront offer price represents a 27-percent premium over Blueprint's closing price on May 30, 2025, and a premium of approximately 34 percent over the 30 trading days of its volume-weighted average price (VWAP) as of May 30, 2025. The purchase will also include the latter's rare immunology disease medicine, Ayvakit/Ayvakyt (avapritinib), the only approved medicine for advanced and indolent systemic mastocytosis (ASM & ISM). READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
3 days ago
- Business
- Yahoo
Why Blueprint Medicines Corporation (BPMC) Skyrocketed On Monday
We recently published a list of . In this article, we are going to take a look at where Blueprint Medicines Corporation (NASDAQ:BPMC) stands against other top-performing stocks on Monday. Blueprint Medicines soared by 26.09 percent on Monday to close at $127.79 each following news that it is set to be acquired by French pharmaceutical giant Sanofi for $9.1 billion. Under the agreement, Sanofi will commence a tender offer to acquire shares of Blueprint Medicines Corporation (NASDAQ:BPMC) at a price of $129 apiece for a total equity value of $9.1 billion. A doctor examining a patient's samples in a modern hospital setting. In addition, shareholders will be able to receive one non-tradable contingent value right (CVR), which will entitle them to two potential milestone payments of $2 and $4 per CVR for the achievement, respectively, of future development and regulatory milestones for BLU-808. The upfront offer price represents a 27-percent premium over Blueprint's closing price on May 30, 2025, and a premium of approximately 34 percent over the 30 trading days of its volume-weighted average price (VWAP) as of May 30, 2025. The purchase will also include the latter's rare immunology disease medicine, Ayvakit/Ayvakyt (avapritinib), the only approved medicine for advanced and indolent systemic mastocytosis (ASM & ISM). READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Business Insider
3 days ago
- Business
- Business Insider
Blueprint Medicines (BPMC) was downgraded to a Hold Rating at TD Cowen
TD Cowen analyst Marc Frahm downgraded Blueprint Medicines (BPMC – Research Report) to a Hold today and set a price target of $130.00. Confident Investing Starts Here: Frahm covers the Healthcare sector, focusing on stocks such as Incyte, Inozyme Pharma, and Xilio Therapeutics. According to TipRanks, Frahm has an average return of 3.7% and a 39.53% success rate on recommended stocks. In addition to TD Cowen, Blueprint Medicines also received a Hold from J.P. Morgan's Brian Cheng in a report issued today. However, on the same day, Citi reiterated a Sell rating on Blueprint Medicines (NASDAQ: BPMC). The company has a one-year high of $121.90 and a one-year low of $73.04. Currently, Blueprint Medicines has an average volume of 988.3K. Based on the recent corporate insider activity of 68 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BPMC in relation to earlier this year. Most recently, in March 2025, Jeffrey Albers, a Director at BPMC sold 5,766.00 shares for a total of $512,020.80.
Yahoo
3 days ago
- Business
- Yahoo
Sanofi Expands Rare Immunology Portfolio With Blueprint Buyout
Sanofi SA (NASDAQ:SNY) on Monday agreed to acquire Blueprint Medicines Corporation (NASDAQ:BPMC). The acquisition includes a rare immunology disease medicine, Ayvakit/Ayvakyt (avapritinib), approved in the U.S. and the EU, and a promising advanced and early-stage immunology pipeline. Ayvakit/Ayvakyt is the only approved medicine for advanced and indolent systemic mastocytosis (ASM & ISM), a rare immunology disease, which is characterized by the accumulation and activation of aberrant mast cells in bone marrow, skin, the gastrointestinal tract, and other organs. The acquisition will also include elenestinib, a next-generation medicine for SM, and BLU-808, a highly selective and potent oral wild-type KIT inhibitor with the potential for immunology will pay $129.00 per share in cash, representing an equity value of approximately $9.1 billion. Blueprint shareholders will also receive one contingent value right (CVR), which entitles the holder to two potential milestone payments of $2 and $4 per CVR to achieve future development and regulatory milestones for BLU-808. The total equity value of the transaction, including potential CVR payments, represents approximately $9.5 billion on a fully diluted basis. Paul Hudson, CEO of Sanofi, said, 'The proposed acquisition of Blueprint Medicines represents a strategic step forward in our rare and immunology complements recent acquisitions of early-stage medicines that remain our main field of interest. Sanofi still retains a sizeable capacity for further acquisitions.' Ayvakit achieved net revenues of $479 million in 2024 and nearly $150 million in Q1 2025, representing year-on-year growth of more than 60% over Q1 2024. Sanofi currently expects to complete the acquisition in the third quarter of 2025. The acquisition will not significantly impact Sanofi's financial guidance for 2025. It is immediately accretive to gross margin and accretive to business operating income and EPS after 2026. In another development, Sanofi exercised its option to exclusively license Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) STAT6 program on Monday, including the drug development candidate NX-3911, an oral, highly selective STAT6 degrader. STAT6 (signal transducer and activator of transcription 6) plays a central role in type 2 inflammation, which drives diseases such as atopic dermatitis and asthma. Under its 2019 collaboration agreement, Nurix will receive a $15 million license extension fee from Sanofi, bringing the total amount received under this collaboration to $127 million. Nurix is eligible for an additional $465 million in development, regulatory, and commercial milestones associated with the STAT6 program and potential future royalties and retains an option to co-develop and co-promote in the U.S. Price Action: SNY stock is trading lower by 0.73% to $49.01, BPMC stock is trading higher by 26.8% to $128.50, and NRIX stock is trading lower by 0.28% to $10.60 during the premarket session at last check Monday. Read Next:Photo by HJBC via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? SANOFI (SNY): Free Stock Analysis Report BLUEPRINT MEDICINES (BPMC): Free Stock Analysis Report This article Sanofi Expands Rare Immunology Portfolio With Blueprint Buyout originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved.
Wall Street Journal
4 days ago
- Business
- Wall Street Journal
Sanofi to Acquire Blueprint Medicines for Up to $9.5 Billion
Sanofi SAN -4.84%decrease; red down pointing triangle agreed to buy Blueprint Medicines BPMC -1.66%decrease; red down pointing triangle, a U.S. pharmaceutical company that specializes in rare immunological diseases, for up to $9.5 billion in a deal that seeks to strengthen the French drugmaker's immunology portfolio. The deal includes a drug for systemic mastocytosis, a rare immunology disease, approved in the U.S. and the European Union under the brand names Ayvakit and Ayvakyt as well as an early-stage immunology pipeline, the companies said Monday. Sanofi agreed to pay $129 a share in cash at closing and a contingent value right that will entitle Blueprint shareholders to receive two potential milestone payments of $2 and $4 subject to the achievement of certain development and regulatory milestones, the companies said. Shares in Nasdaq-listed Bluprint closed at $101.35 on Friday. Write to Adrià Calatayud at
